J.P. Morgan raises Pfizer stock target to USD 30.00

Published on 10/19/2026 at 09:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer reported USD 15.03 billion in second-quarter revenue. Pfizer stock costs EUR 26.29 on October 19, 2026, 0.04 percent below Xetra close.

Dates and operating figures

J.P. Morgan lifted Pfizer's target to USD 30.00 on October 9, 2026.
Second-quarter 2026 revenue reached USD 15.03 billion.
Pfizer stock trades at EUR 26.29 at 9:04 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.04 percent below the Xetra close of October 16, 2026.
Pfizer plans to report third-quarter 2026 results on November 3, 2026.

Moderner Architektur-Render eines unbeschrifteten Glas-Hochhauses, Symbolbild für Pfizer Inc — Architektur-Render eines modernen Glas-Hochhauses steht sinnbildlich für Pfizer Inc., ISIN US7170811035, Pharma-Konzern, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) drew a higher J.P. Morgan target of USD 30.00 from USD 28.00 on October 9, 2026, according to Boerse Express. At Lang & Schwarz, the stock was trading at EUR 26.29 on October 19, 2026 at 9:04 a.m. CEST, 0.04 percent below the Xetra close of October 16, 2026 at EUR 26.30.

Targets rise before the next report

The target change came as analysts reassessed Pfizer's oncology pipeline and recent regulatory progress. The same Boerse Express report said Jefferies raised its target from USD 35.00 to USD 36.00 on October 8, 2026 and retained a Buy rating. Those targets remain dollar-based and are separate from the euro quotation in Germany.

What does the quarter mean?

Pfizer's second-quarter 2026 revenue was USD 15.03 billion, while adjusted diluted earnings per share reached USD 0.77. The earnings call transcript carried by Yahoo Finance said full-year 2026 revenue guidance rose to USD 60.50 billion to USD 62.50 billion from USD 59.50 billion to USD 60.50 billion. That is a USD 1.00 billion increase at the top of the range and a USD 1.50 billion increase at the midpoint.

Three events set the timeline

On October 5, 2026, a Florida legal action involving COVID-19 vaccine statements was reported. On October 6, 2026, Pfizer declared a fourth-quarter cash dividend of USD 0.43 per share. On October 9, 2026, J.P. Morgan raised its price target from USD 28.00 to USD 30.00, the latest dated item in the sequence.

Dates for the next catalyst

Pfizer is scheduled to report third-quarter 2026 results on November 3, 2026, a date listed in the company's public communications on Pfizer. The fourth-quarter dividend record date is November 6, 2026, with payment scheduled for December 7, 2026.

Stock stays near its yearly range

The euro quotation sits within a 52-week range of EUR 20.72 to EUR 26.64 for the PFE.DE listing. The narrow daily move leaves the analyst revisions and the November reporting date as the main measurable reference points for the stock.

The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.